quantisnow
FeedTopReportsPricing
⌘K
Live feed
16:02:10·415d
SECFiling
ChromaDex Corporation logo

ChromaDex Corporation filed SEC Form 8-K: Results of Operations and Financial Condition, Regulation FD Disclosure, Financial Statements and Exhibits

CDXC· ChromaDex Corporation
Health Care
Original source

Companies

  • CDXC
    ChromaDex Corporation
    Health Care

Recent analyst ratings

  • Aug 16UpdateOppenheimer-
  • Aug 11UpdateB. Riley Securities$2.40
  • Mar 10UpdateB. Riley Securities$8.00
  • Mar 8UpdateROTH Capital$7.00
  • Aug 4UpdateHC Wainwright & Co.$12.00

Related

  • SEC400d
    ChromaDex Corporation filed SEC Form 8-K: Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Regulation FD Disclosure, Financial Statements and Exhibits
  • PR406d
    ChromaDex Corp. Announces Name Change to Niagen Bioscience, Inc. and New Ticker Symbol "NAGE" Effective March 19, 2025
  • PR408d
    ChromaDex to Present at the 37th Annual Roth Conference
  • INSIDER409d
    SVP, General Counsel Lopez Carlos Luis bought $2,146 worth of shares (273 units at $7.86), increasing direct ownership by 14% to 2,251 units (SEC Form 4)
  • PR415d
    ChromaDex Corporation Reports Fourth Quarter and Fiscal Year 2024 Results
  • SEC415d
    SEC Form 10-K filed by ChromaDex Corporation
  • INSIDER420d
    SEC Form 4 filed by Chief Executive Officer Fried Robert N
  • SEC420d
    ChromaDex Corporation filed SEC Form 8-K: Leadership Update, Financial Statements and Exhibits
quantisnow

Real-time market intelligence for retail investors. Press releases, filings, ratings, and insider flow - all in one stream.

All systems operational

Feeds

Press releasesAnalyst ratingsInsider tradingFDASECRSS feeds

Top lists

TrendingBy market capActive companiesAnalyst upgradesInsider purchasesFDA approvalsSEC filingsSectorsMarket reports

Company

AboutPricingPublish with usContact

Legal

Terms of usePrivacy policyCookie policy

© 2026 quantisnow.com · Democratizing insights since 2022